ViroMed Moves Ahead With Diabetic Neuropathy Gene Therapy
This article was originally published in PharmAsia News
Executive Summary
Amid challenges elsewhere for gene therapies, South Korea's ViroMed has taken a step further into the U.S. market for its biologics with the recent approval from the FDA to start a Phase III clinical study with its gene therapy for diabetic peripheral neuropathy (DPN).